Edwards Lifesciences Corporation (NYSE:EW) - Investment analysts at SunTrust Banks cut their Q2 2018 EPS estimates for Edwards Lifesciences Corporation in a research report issued on Monday. SunTrust Banks analyst B. Nudell now forecasts that the medical research company will post earnings of $0.99 per share for the quarter, down from their prior estimate of $1.00. SunTrust Banks has a “Buy” rating and a $14.00 price objective on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q3 2018 earnings at $0.93 EPS, Q4 2018 earnings at $1.05 EPS and FY2021 earnings at $5.71 EPS.
Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The firm had revenue of $883.50 million during the quarter, compared to analyst estimates of $776.51 million. During the same quarter in the prior year, the business posted $0.71 earnings per share. Edwards Lifesciences Corporation’s revenue for the quarter was up 26.7% compared to the same quarter last year.
Other analysts have also recently issued reports about the stock. Vetr upgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating and set a $111.50 price target for the company in a report on Tuesday, March 28th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Thursday, May 18th. BidaskClub cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 price target for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and a consensus target price of $116.99.
Shares of Edwards Lifesciences Corporation (EW) traded down 1.19% during trading on Wednesday, reaching $118.00. 711,541 shares of the company traded hands. The firm has a market capitalization of $24.76 billion, a PE ratio of 39.23 and a beta of 0.64. The firm has a 50-day moving average price of $117.42 and a 200-day moving average price of $103.28. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75.
A number of large investors have recently bought and sold shares of EW. Quadrant Capital Group LLC increased its stake in shares of Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock valued at $109,000 after buying an additional 41 shares in the last quarter. YorkBridge Wealth Partners LLC bought a new position in shares of Edwards Lifesciences Corporation during the first quarter valued at about $110,000. NEXT Financial Group Inc increased its position in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the period. Laurel Grove Capital LLC bought a new position in shares of Edwards Lifesciences Corporation during the second quarter valued at about $201,000. Finally, TNB Financial bought a new position in shares of Edwards Lifesciences Corporation during the second quarter valued at about $204,000. Hedge funds and other institutional investors own 83.62% of the company’s stock.
In related news, VP Donald E. Bobo, Jr. sold 5,600 shares of the business’s stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. In the last three months, insiders sold 252,101 shares of company stock worth $28,141,680. Insiders own 2.13% of the company’s stock.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
